600276 恒瑞醫藥
按盤價 
46.100 -0.010 (-0.022%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 20,189,304 | 18.67% | 22,819,785 | 21,275,271 | 25,905,526 | 27,734,599 | |
| 減：營業總成本 | 15,089,979 | 13.81% | 18,214,153 | 17,747,084 | 21,792,969 | 21,282,046 | |
| 其中:營業成本 | 2,833,183 | 6.61% | 3,525,248 | 3,486,639 | 3,741,799 | 3,348,690 | |
| 財務費用 | (447,888) | 20.58% | (478,390) | (470,867) | (337,956) | (181,744) | |
| 資產減值損失 | 9,250 | -172.78% | (107,217) | (146,684) | (13,861) | (7,278) | |
| 公允價值變動收益 | 9,530 | -126.64% | (58,257) | 76,503 | 36,233 | 16,497 | |
| 投資收益 | (31,420) | 171.67% | (49,157) | 387,365 | 213,434 | 341,425 | |
| 其中：對聯營企業和合營企業的投資收益 | (54,228) | 15.10% | (72,696) | (62,996) | (6,940) | -- | |
| 營業利潤 | 5,345,291 | 35.62% | 4,909,905 | 4,111,960 | 4,664,816 | 7,007,072 | |
| 利潤總額 | 5,086,740 | 33.43% | 4,667,110 | 3,968,492 | 4,466,309 | 6,895,480 | |
| 減：所得稅費用 | 470,410 | 30.18% | 389,289 | 153,351 | (17,718) | 586,587 | |
| 淨利潤 | 4,616,330 | 33.77% | 4,277,821 | 3,815,142 | 4,484,027 | 6,308,893 | |
| 減：非控股權益 | (3,246) | -85.73% | (24,615) | (91,233) | (46,191) | (19,490) | |
| 股東淨利潤 | 4,619,576 | 32.98% | 4,302,436 | 3,906,375 | 4,530,218 | 6,328,383 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.730 | 32.73% | 0.680 | 0.610 | 0.710 | 0.990 | |
| 每股派息 (元) * | -- | -- | 0.200 | 0.160 | 0.160 | 0.200 | |
| 每股淨資產 (元) * | 6.861 | 10.42% | 6.344 | 5.929 | 5.473 | 5.721 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 27/12/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
